SBIR Phase I: COVID-19 Rapid Sensing Using Structural DNA Biosensor

SBIR 第一阶段：使用结构 DNA 生物传感器快速传感 COVID-19

• 批准号: 2027816
• 负责人: Xiaohu Yao
• 金额: $ 24.84万
• 依托单位: ATOM BIOWORKS INC
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-06-01 至 2021-12-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2027816&HistoricalAwards=false
• 关键词: SBIR; Phase; COVID; 19; Rapid

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project will be the development of a new rapid COVID-19 virus diagnostic system that recognizes specific virus surface characteristics and generates accurate results within minutes. The current viral diagnostics standard involves complex instruments and technical expertise to run, taking hours to produce and interpret a result. The proposed technology is a sensor that selectively interacts with the COVID-19 virus to produce visible results without expensive instruments or time-consuming procedures. The fundamental technology can also be adapted to rapidly and cheaply develop new diagnostic tests. The lower cost of the test and faster sample-to-result time will greatly improve disease measurement and control, supporting public health needs. This project proposes to develop a highly functional, sensitive and specific diagnostic for the diagnosis of coronavirus based on a Pattern-Recognition Enhanced Sensing and Therapeutics (PEST) concept. The proposed diagnostic solution uses algorithmically designed structural DNA to form a trap that will detect the “signature pattern” of the pathogen and selectively bind to it to generate a signal, without the need of DNA/RNA preprocessing or amplification associated with the current state of practice. The proposed work is to build a pre-clinical prototype of PEST-enabled lateral flow-based COVID-19 rapid diagnostics; the technical performance goal is a sample-to-result time of 5 minutes. The proposed work will also perform pre-clinical validation to validate its specificity and detection limit, as well as implement mechanisms to improve the assay specificity to avoid cross-reaction to other virus types in the Coronavirus family.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

这项小型企业创新研究（SBIR）I期项目的更广泛的影响/商业潜力将是开发新的快速Covid-19病毒诊断系统，该系统识别特定的病毒表面特征并在几分钟内产生准确的结果。当前的病毒诊断标准涉及复杂的工具和技术专业知识，需要花费数小时才能产生和解释结果。所提出的技术是一种传感器，可选择性地与COVID-19病毒相互作用，以产生可见的结果，而无需昂贵的仪器或耗时的程序。基本技术也可以适应快速，廉价地开发新的诊断测试。测试的较低成本和更快的样本到分期时间将大大改善疾病的测量和控制，从而支持公共卫生需求。该项目的建议是基于模式识别增强的感应和疗法（PEST）概念，为冠状病毒的诊断提供高度功能，敏感和特定的诊断。提出的诊断解决方案使用算法设计的结构DNA形成陷阱，该陷阱将检测病原体的“签名模式”并选择性地结合以产生信号，而无需DNA/RNA预处理或与当前实践状态相关的DNA/RNA。拟议的工作是建立一个基于害虫侧流的Covid-19快速诊断的临床前原型。技术绩效目标是5分钟的样本与分辨时间。拟议的工作还将执行临床前验证，以验证其特异性和检测限制，以及实施机制，以提高测定特异性，以避免冠状病毒家族中与其他病毒类型的交叉反应。该奖项反映了NSF的法定任务，并认为通过基金会的知识优点和广泛的crietia criperia criperia criperia criperia criperia criperia criperia criperia criperia recectia rection the Croperia均值得通过评估。